MOLECULAR MECHANISMS OF COLLAGEN DEGRADATION BY ORAL MUCOSAL FIBROBLASTS
口腔粘膜成纤维细胞降解胶原蛋白的分子机制
基本信息
- 批准号:6296242
- 负责人:
- 金额:$ 4.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-12-01 至 2000-04-30
- 项目状态:已结题
- 来源:
- 关键词:antisense nucleic acid blocking antibody collagen collagenase enzyme activity enzyme induction /repression enzyme mechanism fibroblasts gene expression human tissue in situ hybridization laboratory mouse oral mucosa phenotype polymerase chain reaction protein degradation protein sequence stromelysin tissue inhibitor of metalloproteinases western blottings zymogens
项目摘要
Project 3 will investigate the enzymatic mechanisms used by oral mucosal
fibroblasts to degrade interstitial collagen fibrils. The metabolic
degradation of interstitial collagen fibrils by stromal cells may involve
as many as five different gene products, three matrix metalloproteinases,
fibroblast-type collagenase (F-CL), stromelysin-1 (SL-1) and Mr 72K
gelatinase (GL), and two endogenous inhibitors, TIMP-1 and TIMP-2. F-CL
plays a pivotal role in this process because of its ability to cleave
native collagen molecules at catalytically meaningful rates and thereby
initiate the dissolution of the collagen fibril network. We propose to
investigate the peri- and extracellular molecular reactions that enable
human oral mucosal fibroblasts to degrade interstitial collagen fibrils.
We shall initially generate a library of human oral mucosal fibroblast
clones to determine whether natural differences in collagen-degrading
capacity are encoded in expression of particular combinations of
metalloproteinase and inhibitor genes. Collagen-degrading ability will
be determined by monitoring the dissolution of reconstituted fibrils of
type I collagen by live cells. These studies will be extended by
selective induction or abrogation of expression of targeted genes by
growth factors and cytokines, and by antisense deoxyoligonucleotides.
In addition, the role of individual gene products will be assessed by use
of function-perturbing antibodies that block enzymatic or inhibitory
activities. The primary focus will be on the pericellular activation of
proCL because this step is rate-limiting in the cell-mediated dissolution
of collagen fibrils. The roles played by plasminogen, SL-1 and TIMPs in
collagen degradation in general and in activation of proCL in particular
will be examined. We speculate that pericellular proteolysis mediated
by live cells seeded in contact with a solid phase substrate involves
three distinct compartments, the medium, the cell surface and the matrix
surface. We will deduce the component molecular reactions in each of the
three peri-cellular compartments based on identification and tracking of
intermediates and products. Reaction products formed during the process
will be isolated by alpha2M- and TIMP-capture techniques and identified
either by NH2-terminal sequence analysis or by Western analysis using
sequence-specific antibodies. the fate of fragments of collagen
molecules or alpha-chains released from the fibril network will be
monitored to determine whether the Mr 72K GL which is constitutively
expressed by the cells plays a role in this process and whether the
degradative process involves specific surface binding, internalization
and phagolysosomal degradation of collagen chain fragments.
项目3将研究口腔粘膜的酶机制,
成纤维细胞降解间质胶原纤维。 代谢
基质细胞降解间质胶原纤维可能涉及
多达五种不同的基因产物,三种基质金属蛋白酶,
成纤维细胞型胶原酶(F-CL)、基质溶解素-1(SL-1)和Mr 72 K
明胶酶(GL)和两种内源性抑制剂TIMP-1和TIMP-2。 F-CL
在这一过程中起着关键作用,因为它能够切割
天然胶原蛋白分子在催化有意义的速率,从而
引发胶原纤维网络的溶解。 我们建议
研究细胞内和细胞外分子反应,
人口腔粘膜成纤维细胞降解间质胶原纤维。
我们将首先建立一个人口腔粘膜成纤维细胞库
克隆,以确定胶原降解的天然差异是否
能力被编码在特定组合的表达中,
金属蛋白酶和抑制剂基因。 胶原蛋白降解能力将
通过监测以下物质的重构原纤维的溶解来确定:
I型胶原蛋白。 这些研究将扩展到
选择性诱导或消除靶基因的表达,
生长因子和细胞因子以及反义脱氧寡核苷酸。
此外,个别基因产物的作用将通过使用
功能干扰抗体阻断酶或抑制
活动 主要的焦点将是细胞周围的激活,
proCL,因为该步骤在细胞介导的溶出中是限速的
胶原蛋白纤维。 纤溶酶原、SL-1和TIMPs在血管内皮细胞凋亡中的作用
胶原蛋白降解,特别是在proCL活化中
将被审查。 我们推测细胞周围蛋白水解介导的
通过与固相基质接触接种的活细胞,
三个不同的隔室,培养基,细胞表面和基质
面 我们将推导出每一个分子反应的组成部分,
基于识别和跟踪的三个细胞周围区室
中间体和产品。 在该过程中形成的反应产物
将通过α 2 M-和TIMP-捕获技术分离并鉴定
通过NH 2-末端序列分析或通过Western分析,
序列特异性抗体。 胶原蛋白碎片的命运
从原纤维网络释放的分子或α-链将
监察,以确定72 K GL先生是否符合宪法
细胞表达的蛋白质在这一过程中发挥作用,
降解过程涉及特异性表面结合、内化
和胶原蛋白链片段的吞噬溶酶体降解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HENNING BIRKEDAL-HANSEN其他文献
HENNING BIRKEDAL-HANSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HENNING BIRKEDAL-HANSEN', 18)}}的其他基金
MOLECULAR MECHANISMS OF COLLAGEN DEGRADATION BY ORAL MUCOSAL FIBROBLASTS
口腔粘膜成纤维细胞降解胶原蛋白的分子机制
- 批准号:
6104726 - 财政年份:1998
- 资助金额:
$ 4.21万 - 项目类别:
MOLECULAR MECHANISMS OF COLLAGEN DEGRADATION BY ORAL MUCOSAL FIBROBLASTS
口腔粘膜成纤维细胞降解胶原蛋白的分子机制
- 批准号:
6270276 - 财政年份:1997
- 资助金额:
$ 4.21万 - 项目类别:
MOLECULAR MECHANISMS OF COLLAGEN DEGRADATION BY ORAL MUCOSAL FIBROBLASTS
口腔粘膜成纤维细胞降解胶原蛋白的分子机制
- 批准号:
6238396 - 财政年份:1996
- 资助金额:
$ 4.21万 - 项目类别:
相似海外基金
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10279706 - 财政年份:2021
- 资助金额:
$ 4.21万 - 项目类别:
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10693288 - 财政年份:2021
- 资助金额:
$ 4.21万 - 项目类别:
Study of suppressing effect by PAD4 catalytic cleft blocking antibody to rheumatoid arthritis and interstitial pneumonitis
PAD4催化裂隙阻断抗体对类风湿性关节炎和间质性肺炎抑制作用的研究
- 批准号:
17K09982 - 财政年份:2017
- 资助金额:
$ 4.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
用于治疗乳腺癌的 GPCR 阻断抗体的表征。
- 批准号:
8199615 - 财政年份:2011
- 资助金额:
$ 4.21万 - 项目类别:
Regulation of the IL-31 function by the blocking antibody to IL-31 receptor
IL-31 受体阻断抗体对 IL-31 功能的调节
- 批准号:
22591230 - 财政年份:2010
- 资助金额:
$ 4.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The detection of blocking antibody against plasma thrombopoietin in subjects with childhood idiopathic thrombocytopenic purpura
儿童特发性血小板减少性紫癜患者血浆血小板生成素阻断抗体的检测
- 批准号:
13670842 - 财政年份:2001
- 资助金额:
$ 4.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)